Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

2 terminated/withdrawn out of 12 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

7(63.6%)

Phase 2

3(27.3%)

N/A

1(9.1%)

11Total

Phase 1(7)

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT04975334Phase 1Completed

Opioid Antagonism in Hypogonadotropic Hypogonadism

Role: lead

NCT05971836Active Not Recruiting

The Molecular Basis of Inherited Reproductive Disorders

Role: lead

NCT07224490Phase 1Recruiting

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Role: lead

NCT05901467Phase 1Terminated

Recall by Genotype: Neuropeptide Stimulation

Role: lead

NCT06994832Not ApplicableCompleted

Using Visual Arrays to Support Understanding of Genetic Risk

Role: lead

NCT04648969Phase 2Completed

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Role: lead

NCT04975347Phase 1Completed

Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank

Role: lead

NCT07224438Phase 2Recruiting

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

Role: lead

NCT05971849Phase 1Completed

Dampening the Reproductive Axis With Continuous Kisspeptin

Role: lead

NCT05896293Phase 2Recruiting

Kisspeptin Administration Subcutaneously to Patients With IHH

Role: lead

NCT05633966Phase 1Completed

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Role: lead

NCT04532801Phase 1Withdrawn

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

Role: lead

All 12 trials loaded